Innovation & Opportunities in Pulmonary Drug Delivery
Guest Post by Craig Dunbar, VP, Product Development, Blend Therapeutics
Big-pharma has long realized the unique value of inhaled therapies to treat chronic diseases by local delivery to the lungs. GlaxoSmithKline’s Advair™ Diskus is in a category on its own in the pharmaceutical industry, having lost US patent protection four years ago while increasing worldwide sales to over $8 billion in 2013. Teva and Sandoz have both admitted defeat in bringing a generic Advair™ on to the US market due to technical complexity and insurmountable regulatory barriers.
2006, the same year that Advair™ was approved, saw the first approval of a pulmonary insulin product, Exubera™, developed by Nektar and Pfizer. This marked a pinnacle of a decade long pursuit of new pulmonary drug development technologies to enable systemic delivery of proteins, with Pfizer having invested $2.8 billion in Exubera™, and competitors Lilly/Alkermes and NovoNordisk/Aradigm following suite with alternative technologies. However, Exubera was dogged by safety concerns, FDA recommending regular lung exams, a 6 month launch delay due to manufacturing difficulties, and poor acceptance by patients, physicians and payers. Just one year after launch the product was pulled from the market, marking the collapse of the pulmonary insulin market.
So where does this leave pulmonary drug delivery today? Mannkind recently (Apr 2, 2014) received an approval recommendation by FDAs advisory committee for Afrezza®, a pulmonary insulin product that improves glycemic control in type 1 and 2 diabetics, opening the way to approval in July of 2014. The boom and bust of the 90s decanted the more robust pulmonary technologies based on particle engineering and simple delivery devices, with Civitas continuing to develop Alkermes’ large porous particle technology for the treatment of Parkinson’s disease, and Pulmatrix developing novel particle engineering technologies for asthma. Further, new drugs, technologies, and clinical development strategies continue to emerge from both big pharma and small biotechs, recognizing the unique opportunities, and challenges, associated with inhaled therapeutics.
On April 29th, from 8-10am, MassBio is hosting a Forum on this important topic entitled Innovation & New Opportunities in Pulmonary Drug Delivery for Local & Systemic Treatment of Chronic Diseases.
Our international line-up of panelists will cover:
- Novel inhaled therapies and therapeutic agents that goes beyond asthma
- State-of-the-art inhalation systems, delivery systems, “smart-delivery” and self-monitoring/dosing devices to improve patient outcomes
- Integrating discovery and pulmonary drug delivery
- Clinical translation using existing and novel pulmonary deposition methods
- Accelerating clinical optimization of inhaled therapeutics
Please join us as this lively, interactive discussion takes us through the journey from discovery to the clinic and learn how new developments in pulmonary drug delivery can change how we think about the treatment of chronic diseases.
About the author: Craig Dunbar is VP of Product Development at Blend Therapeutics in Watertown working on the integration of medicinal chemistry and drug delivery to produce novel nanomedicines. He has previously held positions at Vertex, Alkermes, Advanced Inhalation Research, and GSK.
Guest Posting Disclaimer: Guest Postings on the MassBioHQ blog are submitted by individual guest posters and in no way represent the opinions or endorsement of MassBio or MassBio employees. MassBio does not represent or guarantee the truthfulness, accuracy, or reliability of statements or facts posted under the Guest Postings on the MassBioHQ blog.
Posted on April 18, 2014, in Guest Bloggers, MassBio and tagged Biotech, Craig Dunbar, Drug Delivery, Formulation & Drug Delivery, MassBio, MassBio Forum, Pulmonary Drug Delivery. Bookmark the permalink. Leave a comment.